Clinical Microbiology and Antimicrobial Chemotherapy. 2002; 4(2):157-163
To determine in vitro activity of fusidic acid and other antimicrobials available for topical use against S. aureus isolated from hospitalised patients.
A total of 879 clinical strains of S. aureus isolated in 2000-2001 from patients hospitalised in 17 medical institutions in different parts of Russia - 4 in Central region, 2 in North-West region, 3 in South region, 2 in Volga region, 3 in Ural region, 3 in Siberian region, were included in the study. Susceptibility to fusidic acid and 8 other antimicrobials available for topical use (gentamicin, mupirocin, erythromycin, clindamycin, lincomycin, tetracycline, chloramphenicol, ciprofloxacin) was determined by agar dilution method in accordance with the NCCLS recommendations.
The most potent antimicrobial was fusidic acid to which no resistance was found. The only other antimicrobial with low frequency of resistance was mupirocin (0,3% of the lower-level resistance). The prevalence of MRSA among tested strains was 33,6%. The high rates of resistance were found to erythromycin (39,6%), tetracycline (37,1%), gentamicin (30,7%), clindamycin (27,1%), ciprofloxacin (13,1%) and chloramphenicol (43,1%).
Fusidic acid and mupirocin can by used as the drugs of choice for the treatment of S. aureus infections in Russia. High rate of resistance to chloramphenicol, macrolides, tetracyclines, aminoglycosides and lincosamydes advise not to use these antimicrobials for empiric therapy of S. aureus infections.